Kanghong Pharmaceutical's subsidiary gets trial approval for KH815

Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SZSE:002773) announced that its wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its injectable drug, KH815. Classified as a Class 1 therapeutic biological product, KH815 is indicated for the treatment of advanced solid tumors. The drug is a novel dual-payload antibody-drug conjugate (ADC) targeting TROP2, designed to overcome drug resistance. Preclinical studies have shown that KH815 exhibits potent anti-tumor activity and may offer therapeutic benefits to patients resistant to single topoisomerase inhibitor ADCs. The company advises investors to exercise caution, as the drug's development and clinical trial outcomes are subject to uncertainties.